Exhibit 99.1

Accretive Health Reports Third Quarter 2011 Financial Results

Ÿ         PCARR, as of today, in a range of $960 million to $990 million, up 47%

Ÿ        Net services revenue of $218.9 million, up 38%

Ÿ         Non-GAAP Adjusted EBITDA of $21.7 million, up 87%

Ÿ        Non-GAAP adjusted diluted EPS of $0.11, up 83%

Ÿ         Company revises fiscal year 2011 guidance

CHICAGO, Nov 9, 2011 (BUSINESS WIRE) — Accretive Health, Inc. (NYSE:AH), a leading provider of comprehensive end-to-end healthcare revenue cycle management services and population health management services infrastructure, today announced financial results for the third quarter ended September 30, 2011.

Financial Highlights – Third Quarter 2011

Mary Tolan, Accretive Health’s Founder and Chief Executive Officer, said, “I’m pleased to report that as of today our Projected Contracted Annual Revenue Run-Rate is in the range of $960 million to $990 million, up $313 million, or 47% year-over-year at the midpoint of the range. This is the largest absolute dollar gain in PCARR in our operating history, and underscores that demand for our services remains strong and that the investments we have made in our people and sales capabilities are yielding significant results.

“Our recently announced revenue cycle strategic collaboration with Intermountain Healthcare validates our market position as the partner of leading healthcare systems with strong track records of clinical and operational excellence. More importantly, this agreement places us at the forefront of innovation with the creation of our Center of Excellence in the West, which will serve as a training, research and development vehicle for the benefit of the industry. Finally, we expect this strategic collaboration to increase our penetration in the West, a market where we see great opportunity for future growth.

“In our Quality and Total Cost of Care business, we continue to deliver significant improvements in key operating metrics beyond our initial expectations. We are also working on intra-stay quality enhancement, which we believe has applicability to all hospitals, regardless of whether they have population health contracts. Finally, our Physician Advisory Services business continues to grow at a rapid pace as hospitals face increased regulatory pressures and intensifying recovery audits.”

Financial Review – Third Quarter 2011

Net services revenue for the third quarter of 2011 grew by 38% to $218.9 million, an increase of $60.5 million over the third quarter of 2010. The following is a breakdown of net services revenue for the third quarter of 2011:

Operating margin for the third quarter of 2011 was $49.0 million, or 22.4% of net services revenue, compared with $32.2 million, or 20.3% of net services revenue, for the third quarter of 2010, an increase of 210 basis points.

Infused management and technology expense for the third quarter of 2011 was $21.3 million, or 9.7% of net services revenue, compared with $15.8 million, or 9.9% of net services revenue, for the third quarter of 2010. Selling, general and administrative expenses were $15.5 million for the third quarter of 2011, or 7.1% of net services revenue, compared with $11.9 million, or 7.5% of net services revenue, for the third quarter of 2010.

Non-GAAP adjusted EBITDA for the third quarter of 2011 was $21.7 million, or 9.9% of net services revenue, compared with $11.6 million, or 7.3% of net services revenue, for the third quarter of 2010, an increase of 260 basis points. Excluded from these results, among other things, were non-cash employee stock based compensation expenses of $7.3 million and $5.3 million, respectively. The higher non-GAAP adjusted EBITDA margin for third quarter of 2011 reflects the operating leverage inherent in the company’s business model, in which margins are expected to increase over time as customer contracts mature and as incentive revenue becomes a higher proportion of total net services revenue.

Net income for the third quarter of 2011 was $7.3 million, compared with $2.9 million in the third quarter of 2010. After adjusting for non-cash employee stock based compensation expenses on an after tax basis, non-GAAP adjusted net income for the third quarter of 2011 was $11.7 million, compared with $6.0 million in the third quarter of 2010. Non-GAAP adjusted net income per diluted common share was $0.11 for the third quarter of 2011, an increase of 83% over the adjusted net income per diluted common share of $0.06 in third quarter of 2010.

For the third quarter of 2011, operating cash flow totaled $31.1 million, compared with $9.3 million for the same period of 2010. Free cash flow, defined as operating cash flow less capital expenditures and the acquisition of software, was $28.9 million for the third quarter of 2011, compared with $4.7 million for the same period of 2010. For the nine months ended September 30, 2011, operating cash flow totaled $2.7 million, compared with $7.0 million for the same period of 2010. Free cash flow for the nine months ended September 30, 2011 totaled negative $6.4 million, compared with negative $2.7 million for the same period last year.

At September 30, 2011, Accretive Health’s total cash balance was $182.1 million, compared with $155.6 million at December 30, 2010.

Fiscal Year 2011 Outlook

Reflecting strong year-to-date contract signings, the company has increased its PCARR estimate for December 31, 2011, and now expects PCARR to be in the range of $970 million to $1 billion. This represents a year-over-year increase of 40% at the midpoint of the range, and positions the company with a strong book of business for 2012.

While the company exceeded its original goal for new business signings, several large contracts were signed later in the year than planned, resulting in lower than expected base fee revenue in 2011. As a result, the company is revising its fiscal year 2011 revenue outlook to $820 million to $835 million, which at the midpoint of the range represents growth of 36% over 2010.

The company now expects fiscal year 2011 adjusted EBITDA of $78 million to $82 million. In light of strong year-to-date signings and expansion of its pipeline, the company has and will continue to increase investments to support its growth trajectory. This includes securing new executive appointments to bring substantial new breadth and depth of talent, and expanding its industry leadership position and geographic reach through the recently announced Center of Excellence in the West.

As a result of these factors, the company expects adjusted net income per diluted common share of $0.42 to $0.44 for fiscal year 2011.

Conference Call and Webcast Details

Accretive Health’s management will host a conference call beginning at 7:30 a.m. CST on November 9, 2011 to discuss the company’s quarterly results and business outlook. To participate, please dial 888-396-2386 (617-847-8712 outside the U.S. and Canada) using conference code number 99646574, or visit the Investor Relations section of Accretive Health’s web site at www.accretivehealth.com to access the live webcast. A replay will be available for one week following the conference call at 888-286-8010 (617-801-6888 outside the U.S. and Canada) using conference code number 19189175. A replay of the conference call will also be available online at www.accretivehealth.com.

About Accretive Health

Accretive Health is a leading provider of services to healthcare providers. Our business purpose is to help U.S. hospitals, physicians and other healthcare providers more efficiently manage their revenue cycle operations and population-based health management initiatives. Our distinctive operating model that includes people, processes and sophisticated integrated technology, which we refer to as our solutions, helps our customers realize sustainable improvements in their operating margins and improve the satisfaction of their patients, physicians and staff. Our customers typically are multi-hospital systems, including faith-based or community healthcare systems, academic medical centers and independent ambulatory clinics, and their affiliated physician practice groups. Our revenue cycle solution spans our customers’ entire revenue cycle, unlike competing services that we believe address only a portion of the

revenue cycle or focus solely on cost reductions. Our revenue cycle management customers have historically achieved significant improvements in cash collections measured against the contractual amount due for healthcare services, which we refer to as net revenue yield. Our population health management infrastructure spans the entire healthcare delivery continuum and enables providers to manage the health of their patient populations delivering higher quality care while reducing aggregate cost of care. For more information, please visit www.accretivehealth.com.

Safe Harbor

This press release contains forward-looking statements, including statements regarding expectations for future financial and business performance and market growth, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our Annual Report on Form 10-K filed with the SEC on March 18, 2011, under the heading “Risk Factors”. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual results, performance, or financial condition may vary materially and adversely from those anticipated, estimated, or expected.

All forward-looking statements included in this report are expressly qualified in their entirety by the foregoing cautionary statements. We wish to caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the uncertainties and factors described above, as well as others that we may consider immaterial or do not anticipate at this time. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown uncertainties and factors, including those described above. The risks and uncertainties described above are not exclusive, and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. We assume no, and we specifically disclaim any, obligation to update, amend, or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our periodic reports that we file with or furnish to the U.S. Securities and Exchange Commission.

Accretive Health, Inc.

Condensed Consolidated Statements of Income (Unaudited)

Other operating and Non-GAAP financial data

Accretive Health, Inc.

Condensed Consolidated Balance Sheets

Accretive Health, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

Explanation of Operational Metrics

We define our Projected Contracted Annual Revenue Run-Rate as the expected total net services revenue for the subsequent twelve (12) months for all healthcare providers for which we are providing services that are under contract. We believe that our Projected Contracted Annual Revenue Run-Rate is a useful method to measure our overall business volume at a point in time and changes in the volume of business over time because it eliminates the time impact associated with the signing of new contracts during a quarterly or annual period. Actual revenues may differ from the projected amounts used for purposes of calculating Projected Contracted Annual Revenue Run-Rate, because, among other factors, the scope of services provided to existing customers may change and the incentive fees we earn may be more or less than expected depending on our ability to achieve projected increases in our customers’ net revenue yield and projected reductions in total medical cost of the customers’ patient population.

We define the contracting phase of our sales process as the final stage when we have reached general agreement with the potential customer on scope, business terms and conditions under which our services will be provided and the written contract is in the process of being negotiated and finalized for execution.

Explanation and Use of Non-GAAP Financial Measures

To provide investors with greater insight and a better understanding of how our management and board of directors analyze our financial performance and make operational decisions, we supplement our consolidated financial statements that are presented on a GAAP basis in this press release with the following non-GAAP financial measures: adjusted EBITDA, adjusted net income, and adjusted net income per diluted common share.

These non-GAAP financial measures should not be considered in isolation; they are in addition to, and are not a substitution, for financial performance measures under GAAP. These non-GAAP financial measures may be different from non-GAAP measures used by other companies. Further, we may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations since they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.

We define non-GAAP adjusted EBITDA as net income (loss) before net interest income (expense), income tax expense (benefit), depreciation and amortization expense and share based compensation expense. We define non-GAAP adjusted net income as net income (loss) before share based compensation expense, net of the estimated tax impact of such expense. We define non-GAAP adjusted net income per diluted common share as non-GAAP adjusted net income applicable to common shareholders divided by the weighted average fully diluted common shares outstanding during the period as computed in accordance with GAAP.

We use non-GAAP adjusted EBITDA:

We believe that non-GAAP adjusted EBITDA, non-GAAP adjusted net income, and non-GAAP adjusted net income per diluted common share are useful to investors in evaluating our operating performance for the following reasons:

We understand that, although measures similar to non-GAAP adjusted EBITDA and non-GAAP adjusted net income are frequently used by investors and securities analysts in their evaluation of companies, these measures have limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some of the limitations of these specific non-GAAP financial measures are:

Non-GAAP Adjusted EBITDA

The following table presents a reconciliation of non-GAAP adjusted EBITDA to net income, the most comparable GAAP measure (unaudited; in thousands):

Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income per Diluted Common Share

The following table presents a reconciliation of non-GAAP adjusted net income to net income, the most comparable GAAP measure, details how we calculate non-GAAP adjusted net income per diluted common share, and reconciles non-GAAP adjusted net income per diluted common share to fully diluted earnings per common share, the most comparable GAAP measure (unaudited; in thousands, except share and per share amounts):

Contact:

Accretive Health, Inc.

Francesca Luthi, 312-255-7794

Senior Vice President, Corporate Communications

investorrelations@accretivehealth.com